Relative to SATB2 being a response to chemotherapy predictor, the favorable value of its expression in CRC16 sharply contrasts with its negative therapy-predictive value in different cancers, e.g., head and neck squamous carcinoma61. This evidence concerns the gene SATB2 and cancer.